Mylan settles EpiPen Medicaid rebate case for $465M, stock jumps
Mylan settled with the U.S. Department of Justice to head off potential Medicaid liability claims by federal and state governments.
Mylan settled with the U.S. Department of Justice to head off potential Medicaid liability claims by federal and state governments.
The maker of EpiPen, the life-saving auto-injector for anaphylaxis, is under fire for exorbitant price hikes so much so that even Martin Shkreli called Mylan out for price-gouging last week.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.